Investor Relations

We are at a breakthrough moment for Alzheimer’s disease (AD) research and drug development. At Acumen, we are leveraging decades of learnings to deliver treatments that can truly impact everyone affected by this devastating disease. Alzheimer’s disease is currently estimated to affect approximately seven million people in the United States and approximately 55 million people. Due to the aging population, patient populations in the United States impacted by AD are expected to grow to approximately 13 million people by 2050 without effective preventative measures or safe and effective disease-modifying treatments. By 2050, healthcare costs for AD in the United States alone are estimated to near $1 trillion.

We are advancing sabirnetug (ACU193), a therapeutic candidate designed to have disease-modifying benefits with an improved safety profile, while also potentially providing symptomatic benefit for AD patients. Sabirnetug is the first immunotherapy drug candidate to enter the clinic that was developed to target toxic amyloid-beta (AβOs) oligomers: a primary trigger and persistent driver of Alzheimer’s-associated pathology and neurodegeneration. In addition, we are investigating a blood-brain barrier-penetrating, Aß oligomer-targeted Enhanced Brain DeliveryTM (EBD) therapy for the treatment of AD.